Menumenu
  • Home
  • Drug utilization study Publications

Drug utilization study Publications

Drug utilization study Publications

  • Evaluation of smoking cessation drug use and outcomes in the Netherlands.Abstract

    OBJECTIVE: Several pharmacological therapies are available to help smokers quit. The aim was to investigate the utilisation and effectiveness of smoking cessation drugs in daily practice in the Netherlands. METHODS: Subjects aged >/=18 years with apharmacy prescription of varenicline, bupropion, nicotine replacement therapy (NRT) or nortriptyline between March 2007 and September 2008 were identified from the PHARMO data warehouse, which includes drug dispensing, hospitalisation and other data fromapproximately 2

    Penning-van Beest FJ, Overbeek JA, Smulder s M, van Spiegel PI, Meerding WJ, Herings RM. J Med Econ. 2011 14 (1): 124-9.
  • Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries.Abstract

    AIM: This study was undertaken to increase understanding of the utilization of a newly introduced statin through evaluation of characteristics of ‘real-life’ patients in a pharmacoepidemiology program in the USA, the Netherlands, the UK and Canada.METHODS: This was an observational analysis of prospectively collected data from primary care patients classified as new users of rosuvastatin or any other statin

    McAfee AT, Rodriguez LA, Goettsch WG, Gonzalez-Perez A, Johansson S, Ming EE, Wallander MA, Herings RM. Minerva Cardioangiol. 2010 Dec; 58 (6): 611-22.
  • Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.Abstract

    OBJECTIVE: To evaluate the number of patients reaching stable treatment with a stimulant (methylphenidate or dexamphetamine) or non-stimulant (atomoxetine) attention-deficit/hyperactivity disorder (ADHD) medication approved for use in the Netherlans, and the time to treatment stabilization among children and adolescents aged 6-17 years

    Sasane R, Hodgkins P, Meijer W. Curr Med Res Opin. 2010 Nov; 26 (11): 2565-74.
  • Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.Abstract

    BACKGROUND: The cholinesterase inhibitors (ChEIs) rivastigmine and galantamine have been approved for the treatment of mild to moderate Alzheimer’s disease in the Netherlands. Differences between ChEIs regarding persistence or the use of effectiveoses in daily clinical practice have been observed. However, most studies assessing ChEI discontinuation and associated determinants have been conducted in North America and there is a lack of knowledge about ChEI discontinuation and its determinants indaily clinical practice in Europe

    Kroger E, van Marum R, Souverein P, Egberts T. Drugs Aging. 2010 Aug 1; 27 (8): 663-75.
  • Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.Abstract

    Observational studies on long-term endocrine treatment among breast cancer patients have presented discontinuation rates on tamoxifen, but lack information on the continuance of any endocrine treatment [both tamoxifen and aromatase inhibitors (AIs)within the same cohort. In this study we determined switching rates from tamoxifen to AIs, discontinuation rates of tamoxifen only, discontinuation rates of any endocrine treatment and determinants of first treatment switch and treatment discontinuation

    van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Breast Cancer Res Treat. 2010 Aug; 122 (3): 843-51.
  • Determination of non-treatment with statins of high risk patients in The Netherlands.Abstract

    OBJECTIVE: To determine in the Netherlands what proportions of high risk patients with established cardiovascular disease (CVD) or diabetes mellitus type 2 (DM2) who were not treated with statins on 1 January 2007 and which characteristics were assciated with non-treatment. METHODS: From the IPCI GP database patients were selected who were registered with a GP on 1 January 2007 who had a history of either CVD (CVD patients), DM2 (diabetics) or both (diabetics with CVD)

    van den Haak P, Heintjes E, Plat AW, JanMeerding W, Webb K, Sturkenboom MC, Herings RM. Curr Med Res Opin. 2010 Feb; 26 (2): 271-8.
  • Change of initial oral antidiabetic therapy in type 2 diabetic patients.Abstract

    Objective To explore the ‘real-life’ therapy of type 2 diabetes mellitus with oral antidiabetic drugs (OADs). Methods From the PHARMO Record Linkage System comprising linked drug dispensing and clinical laboratory data from approximately 2.5 millioindividuals in the Netherlands, among others, new users of OADs were identified in the period 1999-2004

    Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R. Pharm World Sci. 2009 Dec; 31 (6): 622-6.
  • Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands.Abstract

    OBJECTIVE: To describe the use of gastroprotection (GP) among new chronic users of NSAIDs in the Netherlands by gastrointestinal (GI) risk factor (RF) score. METHODS: Data for this retrospective follow-up study were extracted from the PHARMO databae. We selected new chronic users of COX-2 inhibitors (coxibs) or traditional NSAIDs (tNSAIDs) between 1st January 2000 and 31st December 2004

    Vander Linden MW, Gaugris S, Kuipers EJ, Vanden Bemt BJ, van Herk-Sukel MP, Herings RM. Curr Med Res Opin. 2009 Jan; 25 (1): 195-204.
  • Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands.Abstract

    BACKGROUND: This study evaluated trends in adjuvant systemic treatment among breast cancer patients and analyzed the factors on which treatment choice was based. PATIENTS AND METHODS: Patients diagnosed with early stage breast cancer in 1990-2006 wre selected from the registry of the Comprehensive Cancer Centre South (n= 8261)

    Sukel MP, van dePoll-Franse LV, Nieuwenhuijzen GA, Vreugden hil G, Herings RM, Coebergh JW, Voogd AC. Eur J Cancer. 2008 Jul 17; 1846-854.
  • Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.Abstract

    OBJECTIVE: To identify determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. By considering the year of the introduction of weekly bisphosphonates important additional information is obtained. METHODS: New fmale users of daily or weekly alendronate or risedronate between 1999 and 2004, aged >or= 45 years were identified from PHARMO RLS, including drug-dispensing and hospitalisation data of > 2 million residents of the Netherlands

    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Curr Med Res Opin. 2008 May; 24 (5): 1337-1344.